{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreief6uhd2u2bvwxd6p7em6ly5xaixvzuc7wcuyjsrdwyiefhywbe5u",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mlqtwencxki2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreib6dpw52hbm6uzg2a4w4rxrxc27tn5tiwa7irm4cp4mmqh664a22i"
    },
    "mimeType": "image/jpeg",
    "size": 142225
  },
  "path": "/news/2026-05-immune-protein-emerges-parkinson.html",
  "publishedAt": "2026-05-13T13:20:24.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Monoclonal antibodies can block a key immune-related protein that drives the spread of brain cell damage in Parkinson's disease (PD). This protein, called glycoprotein nonmetastatic melanoma B (GPNMB), might be part of a promising strategy for developing a treatment that slows disease progression at its earliest stages, according to a study published in Neuron, by researchers at the Perelman School of Medicine at the University of Pennsylvania.",
  "title": "Immune protein emerges as possible target to slow Parkinson's progression"
}